🇺🇸 FDA
Pipeline program

Recombinant tissue plasminogen activator (rt-PA)

BJCYH1893

Approved small_molecule active

Quick answer

Recombinant tissue plasminogen activator (rt-PA) for Pulmonary Thromboembolisms is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Pulmonary Thromboembolisms
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials